Formulation and Invitro Characterization of Fluvoxamine Loaded Nanoparticles
Abstract
Fluvoxamine is an antidepressant that functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. As the biological half-life of the drug is 15.6 hrs and belongs to BCS class II. To overcome these problems, Nanoparticles of Fluvoxamine were formulated by using Ethyl Cellulose, Eudragit RS 100 & Eudragit Rl 100 as a polymer by emulsification method. Among all the 9 formulations F6 formulation is optimized, as it shows maximum drug release at the end of 12hrs which suits the controlled release drug delivery system criteria as per our studies, having acceptable particle size, SEM, and Zeta potential value. From the drug release kinetics of the F8 formulation of Losartan Nanoparticles dispersion, it was concluded that the F8 formulation follows Zero-order drug release with super case II transport mechanism.
Keywords:
Fluvoxamine, Nanoparticles, particle size, SEM and Zeta potential
Downloads
Download data is not yet available.
References
Liversidge M. Nanosizing: a formulation approach for poorlywater-soluble compounds. Eur J Pharm Sci 2003;18:113-20.
Muller. Nanosuspensions as particulate drug formulation in therapy rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3-19.
Liversidge. Surface modified drug nanoparticles, US Patent No. 5; 1992. p. 145-684.
Sucker H, Muller RH, Hildebrand GE. Eds. Pharmaceutical Technology: Modern Dosage forms. WVG MBH, Stuttgart; 1998. p. 383-91.
Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm2004;58:615-9.
Francis D. Ion milling coupled field emission scanning electron microscopy reveals a current misunderstanding of the morphology of polymeric nanoparticles. Eur J Pharm Biopharm2015;89:56-61.
Dong C. Synthesis of magnetic chitosan nanoparticle and its adsorption property for humic acid from aqueous solution. Colloids Surf A 2014;446:179-89.
Qingguo Xu. Nanotechnology approaches for ocular drug delivery, Middle East. Afr J Ophthalmol2013;20:26-37.
Muller RH, Bohm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. medpharm scientific publishers, Stuttgart; 1998. p. 149-74.
Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution, US Patent No. 5; 1999. p. 858, 410.
Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol2004;113:151-70.
Bisrat M, Nystrom C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 1988;47:223-31.
Mosharraf M, Nystrom C. The effect of particle size shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm 1995;122:35-47.
Zhang J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006;323:153-63.
Duchne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm1997;47:15-23.
Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on poly (methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci 2005;24:411-9.
Hui HW, Robinson JR. Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci 1986;75:280-7.
Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci 1980;69:391-4.
Novir SB. Computational investigation of structural and electronic properties of cis and trans structures of fluvoxamine as a nano-drug. Int J ComputTheor Chem 2017;1105:33-45.
Dezani AB, Pereira TM, Caffar AM, Reis JM, Serra CHR. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Braz. J. Pharm. Sci. 2013; 49(4): 853-863.
Triggle, D, J. Angiotensin II Receptor Antagonism: Losartan-Sites and Mechanisms of Action. Clin Ther. 1995; 17(6):1005-1030.
Dahan A, Miller JM, Amidon GL. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs.AAPS J. 2009; 11(4):740-746.
Rao PLKM, Venugopal V, Anil Kumar G, Rajesh B, Prasad GAL and Ravindergoud D. Quantitative Estimation Of Losartan Potassium In Pharmaceutical Dosage Forms By Uv Spectrophotometry. IJRPC 2011, 1(3)
Rao KS, Panda M, Keshar NK. Spectrophotometric methods for the simultaneous estimation of losartan potassium and hydrochlorothiazide in tablet dosage forms. Chron Young Sci 2011;2:155-60.
V. V. Kumar, D. Chandrasekar, S. Ramakrishna, V. Kishan, Y. M. Rao, and P. V. Diwan, “Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics,” International Journal of Pharmaceutics, vol. 335, no. 1-2, pp. 167–175, 2007.
H. Chen, X. Chang, D. Du et al., “Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting,” Journal of Controlled Release, vol. 110, no. 2, pp. 296–306, 2006.
Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003;250: 215-26.
Higuchi T.Mechanism ofsustained action medication. Theroetical analysis of rateof release of solid drugs dispersed in solid matrices. J PharmSci 1963; 51: 1145-9.
Peppas NA.Analysis of Fickianand non-fickiandrug release from polymer. PharmActaHelv 1985; 60: 110-11.
V Jhansipriya Marabathuni, M. Bhavani, M. Lavanya, K. Padmaja, N. Madhavi, P. Babu, Ch. M. M. Prasada Rao. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Asian J. Pharm. Tech. 2017; 7 (3): 137-143. doi: 10.5958/2231-5713.2017.00022.8
Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, Rao CM. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Magnesium. 2017 Sep 27;15(30):15.
BHABANI SHANKAR NAYAK, JHARANA DASH, SUPRAVA SETHY, P. ELLAIAH, and SUROJ SAHOO. “Formulation Design and in Vitro Characterization of Clotrimazole Dental Implant for Periodontal Diseases”. International Journal of Pharmaceutics and Drug Analysis, Feb. 2015, pp. 68-75.
Syed Iqbal Mohiuddin, Mir Mujahid Ali, Md Majid Iqbal, and Anil Kumar Middha. “Formulation and In-Vitro Evaluation of Compression Coated Tablet of Tinidazole for Colon Spe-Cific Drug Delivery System”. International Journal of Pharmaceutics and Drug Analysis, Aug. 2017, pp. 313-2.
B, P., A. Soman, J. Jobin, P. S. Narayanan, and A. P. John. “PLANTS AND PHYTOCONSTITUENTS HAVING SUNSCREEN ACTIVITY”. World Journal of Current Medical and Pharmaceutical Research, Vol. 2, no. 1, Feb. 2020, pp. 14-20, doi:10.37022/WJCMPR.2020.02019.
Archana Tomar, Arpita Singh, Amresh Gupta, and Satyawan Singh, “FLOATING DRUG DELIVERY SYSTEM: A REVIEW”, Int J Indig Herb Drug, pp. 33-39, Feb. 2021.
AVINASH, Arpita Singh, Swarnima Pandey, Mohd Aqil Siddiqui, and Nitish Kumar, “A Brief Review on Nanoparticles: Type of Platforms, Biological synthesis & Evaluation”, Int J Indig Herb Drug, pp. 23-28, Feb. 2021.
Thella, A. B., N. A, T. K, and S. P. P. “Formulation Development And In Vitro Characterization of Atorvastatin Buccal Patches ”. International Journal of Pharmacognosy and Chemistry, June 2020, pp. 1-11, https://saapjournals.org/index.php/ijpc/article/view/8.
Sudhakar Kancharla, Prachetha Kolli, and Dr.K.Venkata Gopaiah. “Nanosuspension Formulation & Evaluation of Ritonavir & Valsartan by Using Poloxamer As a Stabilizing Agent to Enhance the Oral Bio Availability”. International Journal of Health Care and Biological Sciences, Mar. 2021, pp. 04-17, doi:10.46795/ijhcbs.vi.137.
Muller. Nanosuspensions as particulate drug formulation in therapy rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3-19.
Liversidge. Surface modified drug nanoparticles, US Patent No. 5; 1992. p. 145-684.
Sucker H, Muller RH, Hildebrand GE. Eds. Pharmaceutical Technology: Modern Dosage forms. WVG MBH, Stuttgart; 1998. p. 383-91.
Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm2004;58:615-9.
Francis D. Ion milling coupled field emission scanning electron microscopy reveals a current misunderstanding of the morphology of polymeric nanoparticles. Eur J Pharm Biopharm2015;89:56-61.
Dong C. Synthesis of magnetic chitosan nanoparticle and its adsorption property for humic acid from aqueous solution. Colloids Surf A 2014;446:179-89.
Qingguo Xu. Nanotechnology approaches for ocular drug delivery, Middle East. Afr J Ophthalmol2013;20:26-37.
Muller RH, Bohm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. medpharm scientific publishers, Stuttgart; 1998. p. 149-74.
Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution, US Patent No. 5; 1999. p. 858, 410.
Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol2004;113:151-70.
Bisrat M, Nystrom C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 1988;47:223-31.
Mosharraf M, Nystrom C. The effect of particle size shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm 1995;122:35-47.
Zhang J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006;323:153-63.
Duchne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm1997;47:15-23.
Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on poly (methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci 2005;24:411-9.
Hui HW, Robinson JR. Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci 1986;75:280-7.
Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci 1980;69:391-4.
Novir SB. Computational investigation of structural and electronic properties of cis and trans structures of fluvoxamine as a nano-drug. Int J ComputTheor Chem 2017;1105:33-45.
Dezani AB, Pereira TM, Caffar AM, Reis JM, Serra CHR. Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification. Braz. J. Pharm. Sci. 2013; 49(4): 853-863.
Triggle, D, J. Angiotensin II Receptor Antagonism: Losartan-Sites and Mechanisms of Action. Clin Ther. 1995; 17(6):1005-1030.
Dahan A, Miller JM, Amidon GL. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs.AAPS J. 2009; 11(4):740-746.
Rao PLKM, Venugopal V, Anil Kumar G, Rajesh B, Prasad GAL and Ravindergoud D. Quantitative Estimation Of Losartan Potassium In Pharmaceutical Dosage Forms By Uv Spectrophotometry. IJRPC 2011, 1(3)
Rao KS, Panda M, Keshar NK. Spectrophotometric methods for the simultaneous estimation of losartan potassium and hydrochlorothiazide in tablet dosage forms. Chron Young Sci 2011;2:155-60.
V. V. Kumar, D. Chandrasekar, S. Ramakrishna, V. Kishan, Y. M. Rao, and P. V. Diwan, “Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics,” International Journal of Pharmaceutics, vol. 335, no. 1-2, pp. 167–175, 2007.
H. Chen, X. Chang, D. Du et al., “Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting,” Journal of Controlled Release, vol. 110, no. 2, pp. 296–306, 2006.
Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003;250: 215-26.
Higuchi T.Mechanism ofsustained action medication. Theroetical analysis of rateof release of solid drugs dispersed in solid matrices. J PharmSci 1963; 51: 1145-9.
Peppas NA.Analysis of Fickianand non-fickiandrug release from polymer. PharmActaHelv 1985; 60: 110-11.
V Jhansipriya Marabathuni, M. Bhavani, M. Lavanya, K. Padmaja, N. Madhavi, P. Babu, Ch. M. M. Prasada Rao. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Asian J. Pharm. Tech. 2017; 7 (3): 137-143. doi: 10.5958/2231-5713.2017.00022.8
Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, Rao CM. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Magnesium. 2017 Sep 27;15(30):15.
BHABANI SHANKAR NAYAK, JHARANA DASH, SUPRAVA SETHY, P. ELLAIAH, and SUROJ SAHOO. “Formulation Design and in Vitro Characterization of Clotrimazole Dental Implant for Periodontal Diseases”. International Journal of Pharmaceutics and Drug Analysis, Feb. 2015, pp. 68-75.
Syed Iqbal Mohiuddin, Mir Mujahid Ali, Md Majid Iqbal, and Anil Kumar Middha. “Formulation and In-Vitro Evaluation of Compression Coated Tablet of Tinidazole for Colon Spe-Cific Drug Delivery System”. International Journal of Pharmaceutics and Drug Analysis, Aug. 2017, pp. 313-2.
B, P., A. Soman, J. Jobin, P. S. Narayanan, and A. P. John. “PLANTS AND PHYTOCONSTITUENTS HAVING SUNSCREEN ACTIVITY”. World Journal of Current Medical and Pharmaceutical Research, Vol. 2, no. 1, Feb. 2020, pp. 14-20, doi:10.37022/WJCMPR.2020.02019.
Archana Tomar, Arpita Singh, Amresh Gupta, and Satyawan Singh, “FLOATING DRUG DELIVERY SYSTEM: A REVIEW”, Int J Indig Herb Drug, pp. 33-39, Feb. 2021.
AVINASH, Arpita Singh, Swarnima Pandey, Mohd Aqil Siddiqui, and Nitish Kumar, “A Brief Review on Nanoparticles: Type of Platforms, Biological synthesis & Evaluation”, Int J Indig Herb Drug, pp. 23-28, Feb. 2021.
Thella, A. B., N. A, T. K, and S. P. P. “Formulation Development And In Vitro Characterization of Atorvastatin Buccal Patches ”. International Journal of Pharmacognosy and Chemistry, June 2020, pp. 1-11, https://saapjournals.org/index.php/ijpc/article/view/8.
Sudhakar Kancharla, Prachetha Kolli, and Dr.K.Venkata Gopaiah. “Nanosuspension Formulation & Evaluation of Ritonavir & Valsartan by Using Poloxamer As a Stabilizing Agent to Enhance the Oral Bio Availability”. International Journal of Health Care and Biological Sciences, Mar. 2021, pp. 04-17, doi:10.46795/ijhcbs.vi.137.
Published
31/05/2021
Statistics
582 Views | 445 Downloads
Citatons
How to Cite
S. V, N. D. M. A., Ch.Saibabu, and T.Malyadri. “Formulation and Invitro Characterization of Fluvoxamine Loaded Nanoparticles”. International Journal of Health Care and Biological Sciences, May 2021, pp. 43-52, doi:10.46795/ijhcbs.vi.160.
Issue
Section
Research Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.